Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MRTX

Mirati Therapeutics (MRTX) Stock Price, News & Analysis

Mirati Therapeutics logo

About Mirati Therapeutics Stock (NASDAQ:MRTX)

Advanced Chart

Key Stats

Today's Range
$58.70
$58.70
50-Day Range
$58.70
$59.28
52-Week Range
$27.30
$64.41
Volume
N/A
Average Volume
2.76 million shs
Market Capitalization
$4.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRTX Stock News Headlines

Mirati Therapeutics Stock Price History
What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your IRA could be at risk. Here’s how to prepare.tc pixel
See More Headlines

MRTX Stock Analysis - Frequently Asked Questions

Mirati Therapeutics, Inc. (NASDAQ:MRTX) released its earnings results on Monday, November, 6th. The biotechnology company reported ($2.49) EPS for the quarter, topping analysts' consensus estimates of ($2.83) by $0.34. The business's quarterly revenue was up 203.7% compared to the same quarter last year.

Mirati Therapeutics subsidiaries include MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..

Based on aggregate information from My MarketBeat watchlists, some other companies that Mirati Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH), Humana (HUM) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
11/06/2023
Today
8/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRTX
CIK
1576263
Fax
N/A
Employees
587
Year Founded
2013

Profitability

EPS (Trailing Twelve Months)
($12.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$740.87 million
Net Margins
-1,900.65%
Pretax Margin
-1,899.99%
Return on Equity
-82.15%
Return on Assets
-67.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.54
Quick Ratio
7.40

Sales & Book Value

Annual Sales
$12.44 million
Price / Sales
331.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$17.31 per share
Price / Book
3.39

Miscellaneous

Outstanding Shares
70,150,000
Free Float
67,861,000
Market Cap
$4.12 billion
Optionable
Optionable
Beta
0.77

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:MRTX) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners